CRISPR Therapeutics (CRSP) analyst forecast and price target
Analyst forecast
Consensus of 22 analyst ratings
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Needham | Maintained | Buy | $82.00 | Aug 31, 2026 |
| Citizens | Maintained | Market Outperform | $80.00 | Aug 31, 2026 |
| Citizens | Maintained | Market Outperform | $80.00 | Aug 25, 2026 |
| Citigroup | Maintained | Buy | $88.00 from $82.00 | Aug 4, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $80.00 | Jul 8, 2026 |
| Citizens | Maintained | Market Outperform | $80.00 | Jul 6, 2026 |
| Bernstein | Maintained | Market Perform | $56.00 from $50.00 | May 13, 2026 |
| Citigroup | Maintained | Buy | $82.00 from $80.00 | May 6, 2026 |
| Piper Sandler | Maintained | Overweight | $110.00 from $105.00 | Mar 17, 2026 |
| Chardan Capital | Maintained | Buy | $76.00 from $74.00 | Feb 17, 2026 |
| Needham | Maintained | Buy | $82.00 from $80.00 | Feb 13, 2026 |
| Evercore ISI Group | Maintained | Outperform | $74.00 from $62.00 | Feb 13, 2026 |
| TD Cowen | Maintained | Hold | $45.00 from $40.00 | Feb 13, 2026 |
| Citizens | Maintained | Market Outperform | $80.00 from $86.00 | Jan 30, 2026 |
| Needham | Maintained | Buy | $80.00 | Dec 23, 2025 |
| Citizens | Maintained | Market Outperform | $86.00 | Dec 23, 2025 |
| Chardan Capital | Maintained | Buy | $74.00 from $82.00 | Nov 26, 2025 |
| Citigroup | Maintained | Buy | $77.00 from $87.00 | Nov 12, 2025 |
| Baird | Maintained | Neutral | $44.00 from $52.00 | Nov 11, 2025 |
| RBC Capital | Maintained | Sector Perform | $50.00 from $42.00 | Nov 11, 2025 |
Frequently asked questions
What is the price target for CRSP stock?
The average 12-month analyst price target for CRISPR Therapeutics (CRSP) is $82.50, with a high estimate of $88.00 and a low of $80.00, across 4 analysts.
Is CRSP a buy, sell, or hold?
Analysts covering CRISPR Therapeutics currently average a Buy rating: 12 buy, 10 hold and 0 sell, from 22 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for CRSP?
The average price target of $82.50 implies 45.48% upside from the last price of $56.71.
What is the latest analyst rating on CRSP?
On Aug 31, 2026, Needham maintained CRISPR Therapeutics at Buy with a price target of $82.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.